Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) shares dropped 5.3% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $14.30 and last traded at $14.2640. 84,559 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 395,832 shares. The stock had previously closed at $15.06.
Specifically, CFO Xiaofeng Ye sold 5,667 shares of the business's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75. Following the completion of the sale, the chief financial officer owned 147,757 shares of the company's stock, valued at $2,105,537.25. The trade was a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Xiaofeng Ye sold 6,000 shares of the firm's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $13.98, for a total value of $83,880.00. Following the completion of the transaction, the chief financial officer owned 153,424 shares in the company, valued at $2,144,867.52. The trade was a 3.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Analyst Ratings Changes
Several brokerages have recently weighed in on ANL. JonesTrading started coverage on Adlai Nortye in a report on Thursday, May 14th. They set a "buy" rating and a $22.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Adlai Nortye in a research report on Monday, June 22nd. They set an "overweight" rating for the company. Weiss Ratings restated a "sell (e+)" rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Oppenheimer initiated coverage on Adlai Nortye in a research report on Thursday, May 28th. They issued an "outperform" rating and a $32.00 target price for the company. Finally, Wall Street Zen raised shares of Adlai Nortye from a "hold" rating to a "buy" rating in a research note on Saturday, August 22nd. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Adlai Nortye currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.25.
View Our Latest Stock Analysis on Adlai Nortye
Adlai Nortye Price Performance
The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. The firm has a 50 day moving average price of $12.00 and a 200-day moving average price of $11.16.
Hedge Funds Weigh In On Adlai Nortye
Institutional investors and hedge funds have recently modified their holdings of the company. Seven Fleet Capital Management LP acquired a new position in shares of Adlai Nortye during the 2nd quarter worth about $1,302,000. Braidwell LP purchased a new stake in shares of Adlai Nortye in the second quarter valued at about $9,145,000. Boone Capital Management LLC acquired a new stake in Adlai Nortye during the 2nd quarter worth approximately $2,971,000. ADAR1 Capital Management LLC purchased a new position in Adlai Nortye in the 1st quarter valued at $816,000. Finally, Affinity Asset Advisors LLC purchased a new position in Adlai Nortye during the first quarter worth about $1,140,000. Institutional investors and hedge funds own 35.21% of the company's stock.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.